NanoViricides, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘NanoViricides, Inc. – Product Pipeline Review – 2016’, provides an overview of the NanoViricides, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NanoViricides, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of NanoViricides, Inc.

The report provides overview of NanoViricides, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses NanoViricides, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features NanoViricides, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate NanoViricides, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for NanoViricides, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NanoViricides, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

NanoViricides, Inc. Snapshot 6

NanoViricides, Inc. Overview 6

Key Information 6

Key Facts 6

NanoViricides, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

NanoViricides, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

NanoViricides, Inc. - Pipeline Products Glance 12

NanoViricides, Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

NanoViricides, Inc. - Drug Profiles 14

ADIFBase-I 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

DengueCide 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

EKCCide-I 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Herpecide 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

HIVCide-I 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

HIVCide-II 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

NVINF-1 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

NVINF-2 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

RabiCide-I 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecule for Cold Sores 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule for Ebola and Marburg Infections 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Genital Herpes 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Shingles 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NanoViricides, Inc. - Pipeline Analysis 31

NanoViricides, Inc. - Pipeline Products by Target 31

NanoViricides, Inc. - Pipeline Products by Route of Administration 32

NanoViricides, Inc. - Pipeline Products by Molecule Type 33

NanoViricides, Inc. - Pipeline Products by Mechanism of Action 34

NanoViricides, Inc. - Recent Pipeline Updates 35

NanoViricides, Inc. - Dormant Projects 42

NanoViricides, Inc. - Discontinued Pipeline Products 43

Discontinued Pipeline Product Profiles 43

AviFluCide-I 43

FluCideHP-I 43

NanoViricides, Inc. - Locations And Subsidiaries 44

Head Office 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

NanoViricides, Inc., Key Information 6

NanoViricides, Inc., Key Facts 6

NanoViricides, Inc. – Pipeline by Indication, 2016 8

NanoViricides, Inc. – Pipeline by Stage of Development, 2016 10

NanoViricides, Inc. – Monotherapy Products in Pipeline, 2016 11

NanoViricides, Inc. – Preclinical, 2016 12

NanoViricides, Inc. – Discovery, 2016 13

NanoViricides, Inc. – Pipeline by Target, 2016 31

NanoViricides, Inc. – Pipeline by Route of Administration, 2016 32

NanoViricides, Inc. – Pipeline by Molecule Type, 2016 33

NanoViricides, Inc. – Pipeline Products by Mechanism of Action, 2016 34

NanoViricides, Inc. – Recent Pipeline Updates, 2016 35

NanoViricides, Inc. – Dormant Developmental Projects,2016 42

NanoViricides, Inc. – Discontinued Pipeline Products, 2016 43

List of Figures

List of Figures

NanoViricides, Inc. – Pipeline by Top 10 Indication, 2016 8

NanoViricides, Inc. – Pipeline by Stage of Development, 2016 10

NanoViricides, Inc. – Monotherapy Products in Pipeline, 2016 11

NanoViricides, Inc. – Pipeline by Target, 2016 31

NanoViricides, Inc. – Pipeline by Route of Administration, 2016 32

NanoViricides, Inc. – Pipeline by Molecule Type, 2016 33

NanoViricides, Inc. – Pipeline Products by Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports